Clinical-criteria-based prior authorization

Prior authorization for pelvic MRI (with or without contrast) must document that the patient meets the policy clinical criteria (age, PSA/DRE thresholds and specified high‑risk features) because MRI pelvis is appropriate only when those criteria are met.

• Use supporting clinical documentation to show the qualifying criterion (age, PSA, DRE, high‑risk features).

Prior authorization required for indicated MRI pelvis exams

Prior authorization is required when requesting MRI pelvis (with or without contrast) for the listed indications, including initial staging, restaging/recurrence, post‑negative TRUS biopsy scenarios, and solitary PIN follow‑up.

• Indications requiring authorization include solitary PIN repeat imaging, initial work‑up/staging across NCCN risk groups, and restaging/recurrence triggers.

Serial MRI monitoring denied when based on PSA alone

Serial MRI monitoring requested solely to monitor an elevated PSA is considered not medically necessary and will be denied; authorization must include other qualifying criteria if seeking repeat imaging.

• Requests for serial MRI for PSA monitoring alone should not be authorized unless other policy indications are documented.

mpMRI frequency on active surveillance (authorization requirement)

For patients on active surveillance, repeat mpMRI should be authorized only when documentation supports it and the interval should be no more often than every 12 months per NCCN unless there is a clinical indication to shorten the interval.

• Include rationale in authorization if mpMRI is being requested sooner than 12 months (clinical indication required).

Billing/coding: use listed CPTs; removed codes may trigger denial

Claims and prior authorizations may be denied if billing codes do not match the CPT codes listed in the policy (72195, 72197, 77021) or if removed/unmanaged codes are used.

• Avoid using codes 76376, 76377, and 76942 as these were removed/are unmanaged and may trigger denial.
• Use 72195 or 72197 as appropriate for contrast use per the service performed.

Prior authorization dependent on product coverage

If a Medicare product covers the MRI service and there is no national or local Medicare coverage decision, the medical policy criteria in this document apply; verify product coverage before authorization.

• If a product does not cover the service, the medical policy criteria do not apply.

Authorize MRI after negative/non‑diagnostic TRUS biopsy only with specified triggers

If a prior TRUS biopsy was negative or non‑diagnostic, MRI (or MRI/US fusion biopsy) is appropriate only when associated with rising PSA, abnormal DRE, or the need for MR/US fusion biopsy—include those findings in the authorization documentation.

• Document prior TRUS biopsy result and the associated trigger (rising PSA, abnormal DRE, or planned MR/US fusion biopsy).

Document imaging sequencing for very high‑risk staging

For very high‑risk patients, MRI may be obtained in addition to or as part of combination staging studies (e.g., CT chest/abdomen/pelvis, bone scan, or PSMA PET/CT); authorization should document the planned imaging sequence.

• Authorization should specify which combination is planned (CT chest + CT abdomen/pelvis + bone scan; CT chest + CT abdomen + MRI pelvis + bone scan; or PSMA PET/CT).

Document imaging‑guided biopsy pathway and PI‑RADS findings

Follow the MRI‑guided biopsy pathway documentation: if mpMRI is used to triage patients for targeted biopsy, include the PI‑RADS (or Likert) score and the planned targeted biopsy approach to support authorization.

• Indicate whether a targeted biopsy only or targeted plus systematic biopsy is planned and include lesion PI‑RADS scores.

No step therapy requirement described

There are no step therapy requirements described in the policy; do not impose step therapy for MRI of the prostate beyond the stated clinical criteria.

• Policy does not mandate a stepwise trial of other tests before MRI beyond meeting the listed clinical criteria.

Required clinical documentation for authorization

Requests must include required clinical documentation: patient age, a recent PSA value, DRE findings, presence of specified high‑risk features, and prior TRUS biopsy results when applicable to support the requested imaging.

• For staging or restaging include NCCN risk stratification details and relevant prior treatments/imaging.
• For PSA‑based requests include the most recent PSA value and timing.

Supportive clinical documentation required for staging MRI

Provide supportive documentation for staging MRI that demonstrates NCCN initial risk stratification (low, favorable/unfavorable intermediate, high, very high) and the rationale for MRI as part of the staging workup.

• Include the specific risk group and whether MRI is requested to establish active surveillance candidacy or prior to planned treatment.
• For very high‑risk patients, document the intended additional imaging (CT, bone scan, PSMA PET/CT) if applicable.

Support post‑treatment PSA documentation for staging MRI

Documentation supporting staging MRI should include PSA values and timing consistent with recurrence criteria (for example, PSA >0.2 ng/mL on two consecutive measurements) when post‑treatment evaluation is the indication.

• When applicable, include prior imaging and treatments (prostatectomy, radiation, ablation, systemic therapy) in the submission.

Include recent PSA value with PSA‑based imaging requests

Include in authorization requests a recent PSA value when the imaging is being requested on the basis of PSA; lack of a recent PSA is a documentation deficiency and may lead to denial.

• Attach the most recent PSA and date to the prior authorization submission.

Product coverage verification required

Verify product coverage before initiating prior authorization because medical policy criteria apply only when the member's product covers the service.

• If the product does not cover the service, do not submit authorization against this policy.

Clinical step after negative TRUS biopsy — document triggers

If a TRUS biopsy was negative or non‑diagnostic, MRI is appropriate when there is rising PSA, abnormal DRE, or need for MR/US fusion biopsy; include those clinical triggers in the authorization request.

• Document prior biopsy date, result, and the clinical indication prompting MRI.

MR guidance for needle placement is not covered (denial risk)

When requesting MRI guidance for needle placement, be aware that MR guidance for needle placement is considered not medically necessary for prostate biopsy and such requests will be denied.

• Do not submit requests or billing for MR guidance for needle placement to obtain prior authorization under this policy.

Contrast allowed for covered indications

MRI pelvis may be performed with or without contrast; the policy does not restrict contrast use for covered indications.

Indications determine contrast use

MRI pelvis may be performed without contrast, or without and with contrast depending on indication; mpMRI includes both non-contrast and contrast components as appropriate for the clinical scenario.

Permitted modality permutations for MRI pelvis

Policy language specifies acceptable modality permutations (MRI pelvis without and with contrast; or MRI pelvis without contrast alone) and allows either approach for active surveillance as stated in the policy wording.

mpMRI components include DCE

Multiparametric MRI (mpMRI) includes dynamic contrast-enhanced (DCE) imaging as one of the component sequences along with T2 and diffusion-weighted imaging (DWI).

Use CPT 72197 for without‑then‑with contrast MRI

When contrast sequences are performed (without and then with contrast), use CPT 72197 to represent pelvic MRI performed without and then with contrast per the policy code table.

mpMRI approaches referenced; no extra contrast rules

The policy references multiparametric MRI approaches in the literature but does not specify additional administration rules for contrast beyond the indexed indications and coding guidance.

Authorization requires meeting policy criteria

Prior authorization must document that the policy clinical criteria are satisfied for the requested MRI pelvis (with or without contrast).

Authorization required for staging/restaging MRI

Prior authorization is required for MRI pelvis when performed for the listed staging and restaging indications; include supportive clinical detail in the request.

Authorization must show criteria met; serial MRIs not covered

Prior authorization must document that the policy criteria are met (e.g., PSA thresholds, active surveillance indications); serial MRIs requested for PSA monitoring alone are addressed as not medically necessary.

Use listed CPT codes for authorization

Use the policy-provided CPT codes (72195, 72197, 77021) for prior authorization submissions as applicable.

Subject to product coverage and Medicare determinations

Medical policy criteria apply only when the member's product covers the service and when there are no Medicare national/local coverage decisions that supersede; verify product and Medicare determinations.